Why the study?
What are the risks and benefits of nesiritide therapy in patients with acute decompensated heart failure?
What are the risks and benefits of nesiritide therapy in patients with acute decompensated heart failure?
Physicians must carefully reevaluate the use of nesiritide in acute decompensated heart failure due to safety concerns raised by recent meta-analyses, pending further trial data.
Answers are grounded in this paper and cite their sources.
May warrant caution with nesiritide in acute decompensated HF; leaves open confirmation of risks in prospective RCTs.
Standard therapy for acute decompensated heart failure, a major health problem, consists of intravenous diuretics, vasodilators, and positive inotropic agents. Nesiritide, a recombinant form of human B-type natriuretic peptide, is the only drug specifically approved for this indication. Recent meta-analyses have reported an increased risk of worsening renal function and 30-day mortality with nesiritide administration. These data understandably require physicians to carefully reevaluate their current use of nesiritide in patients with acute decompensated heart failure. In performing this reevaluation, it is important to consider our understanding of the underlying disease state, the limitations and results of these meta-analyses, and new data that provide additional insight into the possible risks and benefits associated with nesiritide therapy. Until additional therapeutic trials are conducted, therapeutic choices must be based on symptomatic and hemodynamic improvement and limited, imperfect available data, which may continue to support the use of nesiritide for its established indication.
No takes yet. Share an insight, caveat, or question.
Rohit Arora (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: